ChemoCentryx Phase III ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis Highlighted in Oral Plenary Presentations at EULAR ...
MOUNTAIN VIEW, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today announced presentations highlighting outcomes of the Company’s Phase III ADVOCATE trial as part of the virtual annual meetings of the leading European …